Skip to main content
. 2011 Oct;85(20):10440–10450. doi: 10.1128/JVI.05408-11

Fig. 4.

Fig. 4.

VSV-M(mut)-mp53 protects immunocompetent mice from TS/A-luc formation. (A) Mock- or rVSV-treated mice were anesthetized and injected intraperitoneally (i.p.) with a luciferin substrate, and luciferase activity was detected using the IVIS. Representative images from mock-, VSV-M(mut)-mp53-, and VSV-mp53-treated mice are shown. Luciferase radiance is an indicator of tumor burden and is quantified using Living Image software (right). (B) BALB/c mice (n = 7) were initially given 1 × 105 TS/A-luc cells i.v. on day 0 and were then either mock or rVSV treated [5 × 107 PFU or 5 × 108 PFU VSV-M(mut)-mp53 only] on day 3. The mice were then monitored for survival (*, P = 0.0045; log rank test). (C) Previously treated or naïve mice (n = 4) were challenged with 2 × 105 TS/A-luc cells on day 120 (day 0 for rechallenge), and survival was monitored (*, P = 0.0091; log rank test).